Mallinckrodt is eyeing a broader piece of the MRI contrast market, thanks to recent Food and Drug Administration clearance of its OptiMark contrast agent. OptiMark is designed for use in MR imaging of lesions and tumors of the brain, spine, and liver.The
Mallinckrodt is eyeing a broader piece of the MRI contrast market, thanks to recent Food and Drug Administration clearance of its OptiMark contrast agent. OptiMark is designed for use in MR imaging of lesions and tumors of the brain, spine, and liver.
The segment of the MR market into which OptiMark will be sold is worth more than $150 million annually and is growing at a rate of 12% to 15%, according to the St. Louis-based vendor. Mallinckrodt already sells another MR contrast agent, GastroMark, for use in imaging of the gastrointestinal tract. The company expects to begin shipping OptiMark this quarter.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.